Aimmune Therapeutics (AIMT) Upgraded to Strong-Buy by ValuEngine

ValuEngine upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a buy rating to a strong-buy rating in a report released on Tuesday morning.

Other equities analysts also recently issued reports about the stock. Wedbush reiterated a buy rating on shares of Aimmune Therapeutics in a research note on Friday, February 23rd. BidaskClub downgraded shares of Aimmune Therapeutics from a hold rating to a sell rating in a research note on Thursday, February 22nd. Piper Jaffray Companies set a $62.00 price objective on shares of Aimmune Therapeutics and gave the company a buy rating in a research note on Thursday, April 5th. Credit Suisse Group set a $47.00 price objective on shares of Aimmune Therapeutics and gave the company a buy rating in a research note on Thursday, May 10th. Finally, Zacks Investment Research downgraded shares of Aimmune Therapeutics from a buy rating to a hold rating in a research note on Friday, May 11th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $53.67.

NASDAQ AIMT opened at $33.06 on Tuesday. Aimmune Therapeutics has a 52-week low of $15.97 and a 52-week high of $42.00. The company has a market cap of $1.82 billion, a PE ratio of -12.67 and a beta of -0.36.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.21). During the same quarter in the previous year, the company posted ($0.52) EPS. analysts predict that Aimmune Therapeutics will post -2.79 EPS for the current year.

In related news, insider Mary M. Rozenman sold 1,807 shares of the stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $33.10, for a total transaction of $59,811.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Douglas T. Sheehy sold 3,523 shares of the stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $36.52, for a total transaction of $128,659.96. Following the sale, the insider now directly owns 32,500 shares of the company’s stock, valued at approximately $1,186,900. The disclosure for this sale can be found here. Insiders have purchased 58,093 shares of company stock valued at $1,858,976 in the last three months. 14.70% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. First Republic Investment Management Inc. purchased a new stake in Aimmune Therapeutics during the fourth quarter valued at approximately $202,000. Virtu Financial LLC purchased a new stake in Aimmune Therapeutics during the fourth quarter valued at approximately $239,000. Xact Kapitalforvaltning AB purchased a new stake in Aimmune Therapeutics during the first quarter valued at approximately $207,000. Teacher Retirement System of Texas purchased a new stake in Aimmune Therapeutics during the fourth quarter valued at approximately $282,000. Finally, WINTON GROUP Ltd purchased a new stake in Aimmune Therapeutics during the first quarter valued at approximately $262,000. 81.31% of the stock is owned by institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply